News & Research Archive
All GLP-1 news articles, safety updates, and research summaries, including older items not shown on the homepage.
2025 GLP-1 MDL Milestones & Court Orders
Case counts near 3,000; court sets 2026 expert and summary-judgment deadlines with NAION claims rising.
Safety & Regulatory Highlights (Late 2025)
Alzheimer’s trials fail; CTAD disclosures; Australia TGA adds suicide risk warning to all GLP-1 labels.
Vision Risk Research on Semaglutide (2025)
RVO risk up 1.6x, NAION odds 68.6x higher, and JAMA Ophthalmology incidence at 14.5 per 100k person-years.
Poison control calls surge as GLP-1 drugs gain popularity
Pennsylvania and New Jersey poison control centers described a steep rise in calls related to GLP-1 weight-loss drugs.
Ozempic face and other GLP-1 side effects
Rapid weight loss can cause cosmetic changes along with digestive issues.
Patients sue over alleged side effects of GLP-1 drugs
TIME investigation highlights lawsuits from patients with debilitating side effects.
FDA Reports Multiple Deaths and Hospitalizations from Compounded Semaglutide
Reports include 10 deaths and 100 hospitalizations linked to off-brand compounded semaglutide.
Study Links GLP-1 Drugs to Severe Stomach Problems
JAMA: higher risk of pancreatitis, bowel obstruction, and gastroparesis vs. non-GLP-1 weight loss meds.
Nearly 25,000 Emergency Department Visits Linked to Semaglutide
Annals of Internal Medicine estimates 24,499 ER visits tied to semaglutide in two years post-approval.